Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Authors :: Cassier, Philippe A.
Peyramaure, Clémentine
Attignon, Valery
Eberst, Lauriane
Pacaud, Camille
Boyault, Sandrine
Desseigne, Françoise
Sarabi, Mathieu
Guibert, Pierre
Rochefort, Pauline
Marques, Nathalie
Rivoire, Michel
Dupré, Aurélien
Peyrat, Patrice
Terret, Catherine
Ray-Coquard, Isabelle
Coutzac, Clélia
Pérol, David
Blay, Jean-Yves
Trédan, Olivier
de la Fouchardière, Christelle
Source :: Translational Oncology; January 2022, Vol. 15 Issue: 1
Publication Year :: 2022
Abstract: •Cancers originating in the stomach and oesophagus have poor prognosis and limited treatment options.•Gastroesophageal cancer frequently harbour actionable genomic alterations.•Our data suggest that patients with advanced gastroesophageal cancers and actionable alterations have prolonged survival compared to those who do not.•Comprehensive genotyping, beyond determination of the HER2/ERBB2 status should be implemented early in the management of patients with gastroesophageal cancers.

Full Text Access

Tools